Halozyme Therapeutics, Inc.
|Company Name||Halozyme Therapeutics, Inc.|
On January 16, 2018, an abstract was published detailing a study of Halozyme’s drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX. The abstract’s authors concluded that the addition of PEGPH20 to mFFOX appears to be detrimental, noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, and vomiting. On this news, Halozyme’s share price fell $1.76, or nearly 9%, to close at $17.98 on January 17, 2018, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Halozyme Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.